Martin Felices

Associate Professor

University of Minnesota
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

NK cell tumor infiltration is associated with good prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). NK cells recognize and kill targets by a process called natural cytotoxicity. We hypothesized that promoting an antigen-specific synapse with coactivation may enhance NK cell function in mCRPC. We describe a tri-specific killer engager (TriKE) construct that engages with the activating receptor CD16 on NK cells and prostate-specific membrane antigen (PSMA) on mCRPC cells and has an IL15 moiety that is essential for NK cell survival, proliferation, and priming. We show that the PSMA TriKE specifically binds to PSMA-expressing cells and significantly enhances expansion, degranulation, and cytokine production of NK cells derived from healthy donors or patients with prostate cancer. Bystander killing of PSMA-negative tumor cells was also achieved with PSMA TriKE treatment when cocultured with PSMA-positive cells, suggesting potential PSMA TriKE benefit in controlling tumor antigen escape. When tested under physiologic conditions recapitulating the mCRPC tumor microenvironment, NK cells treated with PSMA TriKE and prolonged exposure to hypoxia or myeloid-derived suppressor cells maintained their potent function whereas IL15-treated NK cells showed greatly impaired cytotoxicity. Finally, in vivo testing of PSMA TriKE showed improved tumor control and survival of mice as compared with IL15-treated and untreated control groups. In conclusion, PSMA TriKE demonstrates potential as a new therapy for advanced prostate cancer by providing additional signals to NK cells to maximize their antitumor potential in prostate cancer, especially in the setting of a hostile tumor microenvironment.

Year:

2025

Purpose: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients. Experimental Design: CD83 expression was evaluated among circulating CD4 + T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD ( n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined. Results: CD83 overexpression on CD4 + T cells correlates with reduced survival and increased TRM. Increased CD83 + B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83 + B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo , without observed myeloablation. Conclusions: CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.

Year:

2025

Collaborators (19)

Yvette Soignier

University of Minnesota Twin Cities

UNITED STATES
View details

Laura Kotz

University of Minnesota Twin Cities

UNITED STATES
View details

Joseph Maakaron

Assistant Professor

University of Minnesota

UNITED STATES
View details

Brian C. Betts

Vice Chair

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Philippa Kennedy

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Daniel Weisdorf

Faculty, Leader

University of Minnesota

UNITED STATES
View details

Najla El Jurdi

Assistant Professor

University of Minnesota

UNITED STATES
View details

Marco Davila

SVP, Translational Research

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Margaret MacMillan

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Bruce Blazar

Regents Professor

University of Minnesota

UNITED STATES
View details

Veronika Bachanova

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Connor Demorest

University of Minnesota

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Xianghua Luo

Professor

University of Minnesota

UNITED STATES
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Jeffrey S Miller

University of Minnesota System

UNITED STATES
View details

Anne Eaton

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Shernan Holtan

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Nicholas Zorko

Assistant Professor

University of Minnesota

UNITED STATES
View details